Related Experiment Videos
CA-50 as tumour marker in transitional bladder carcinoma
British Journal of Urology
|June 1, 1989
Summary
Monoclonal antibody CA-50 shows potential as a bladder cancer marker. Elevated CA-50 levels correlate with higher recurrence rates in bladder cancer patients, particularly in advanced stages.
Area of Science:
- Oncology
- Biomarkers
- Urology
Background:
- Monoclonal antibody CA-50 is an established tumor marker for gastrointestinal carcinoma.
- Its utility in bladder cancer diagnosis and prognosis requires further investigation.
Purpose of the Study:
- To evaluate the diagnostic and prognostic value of monoclonal antibody CA-50 in bladder cancer patients.
- To assess the correlation between CA-50 levels and tumor stage, grade, and recurrence rates.
Main Methods:
- Retrospective analysis of CA-50 levels in bladder cancer patients.
- Comparison of CA-50 levels across different tumor stages (Ta, T1, T3) and grades (G3).
- Assessment of recurrence rates within six months for patients with elevated versus normal CA-50 levels.
Main Results:
- Elevated CA-50 levels were observed in patients with infiltrating and superficial bladder carcinoma.
- A higher recurrence rate within six months was noted in patients with elevated CA-50 levels.
- Mean CA-50 levels were higher in T1 and T3 stage carcinomas compared to normal, with a significant difference noted between Ta and T1+T3 stages.
Conclusions:
- Monoclonal antibody CA-50 may serve as a potential biomarker for bladder cancer.
- Elevated CA-50 levels are associated with increased recurrence risk in bladder cancer.
- Further longitudinal studies with serial CA-50 measurements are warranted to confirm its prognostic role in bladder cancer.